Literature DB >> 2153910

Nonadrenergic [3H]idazoxan binding sites are physically distinct from alpha 2-adrenergic receptors.

M C Michel1, J W Regan, M A Gerhardt, R R Neubig, P A Insel, H J Motulsky.   

Abstract

We have recently demonstrated that the alpha 2-adrenergic radioligand [3H]idazoxan also labels additional sites that do not recognize catecholamines but bind with high affinity several chemically distinct drugs previously assumed to be highly selective for alpha 2-adrenergic receptors [Mol. Pharmacol. 35:324-330 (1989)]. We now have used three approaches to distinguish the nonadrenergic [3H]idazoxan sites from alpha 2-adrenergic receptors. (a) No nonadrenergic [3H]idazoxan binding sites were found in COS-7 cells transfected with the genes for the two known alpha 2-adrenergic receptor subtypes. (b) The ratio of alpha 2-adrenergic and nonadrenergic [3H]idazoxan sites in human platelet membranes varied considerably between various donors. (c) Highly purified platelet plasma membranes were enriched for alpha 2-adrenergic receptors but did not contain any nonadrenergic [3H]idazoxan binding sites. We conclude that the nonadrenergic [3H]idazoxan binding sites are not co-expressed with alpha 2-adrenergic receptors and at least in human platelets may be located in an intracellular compartment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2153910

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  9 in total

1.  Neuroprotection by alpha 2-adrenergic agonists in cerebral ischemia.

Authors:  Yonghua Zhang; Harold K Kimelberg
Journal:  Curr Neuropharmacol       Date:  2005-10       Impact factor: 7.363

2.  Attenuated renal response to moxonidine and rilmenidine in one kidney-one clip hypertensive rats.

Authors:  P Li; S B Penner; D D Smyth
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

Review 3.  G protein-coupled receptors in major psychiatric disorders.

Authors:  Lisa A Catapano; Husseini K Manji
Journal:  Biochim Biophys Acta       Date:  2006-10-03

4.  Contrasting effects of the imidazol(in)e alpha 2-adrenoceptor agonists, medetomidine, clonidine and UK 14,304 on extraneuronal levels of noradrenaline in the rat frontal cortex: evaluation using in vivo microdialysis and synaptosomal uptake studies.

Authors:  J W Dalley; S C Stanford
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

5.  Antagonism by idazoxan at low dose but not high dose, of the natriuretic action of moxonidine.

Authors:  D R Allan; S B Penner; D D Smyth
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

6.  In vivo electrophysiological evidence for tonic activation by endogenous noradrenaline of alpha 2-adrenoceptors on 5-hydroxytryptamine terminals in the rat hippocampus.

Authors:  R Mongeau; P Blier; C de Montigny
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-03       Impact factor: 3.000

7.  Renal imidazoline preferring sites and solute excretion in the rat.

Authors:  D R Allan; S B Penner; D D Smyth
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

8.  Complex stimulus properties of LSD: a drug discrimination study with alpha 2-adrenoceptor agonists and antagonists.

Authors:  D Marona-Lewicka; D E Nichols
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

9.  Effects of the selective I1 imidazoline receptor agonist, moxonidine, on gastric secretion and gastric mucosal injury in rats.

Authors:  G B Glavin; D D Smyth
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.